Aziz Kabeer 4

4 · AN2 Therapeutics, Inc. · Filed Jul 10, 2026

AI-generated summary of this filing

Updated Jul 10, 2026

AN2 Therapeutics (ANTX) Director Aziz Kabeer Receives 2,852-Share Award

What Happened

Aziz Kabeer, a member of AN2 Therapeutics' board of directors, was issued 2,852 shares on 2026-07-10 as an award/compensation. The filing reports an acquisition price of $0.00, giving a reported transaction value of $0. These shares were issued in lieu of cash compensation and vested immediately.

Key Details

Transaction date: 2026-07-10; Price per share: $0.00; Shares acquired: 2,852; Reported value: $0.
Filing date: 2026-07-10 (same day as the transaction in the Form 4).
Vesting/tax note: Footnote F1 — shares issued in lieu of cash compensation under the non-employee director policy; all shares vest immediately.
Related holdings: Footnotes F2 and F3 disclose that certain AN2 shares are held by Adjuvant entities (Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P.). Kabeer is Secretary of the managing entity and may be deemed to share voting/dispositive power over those fund-held securities; those entities disclaim beneficial ownership except for pecuniary interest.
Shares owned after the transaction: Not specified in the filed report.

Context

This was a compensation award (code A) rather than a market purchase or sale; awards issued in lieu of cash are routine for non-employee directors and do not necessarily signal the director’s market view. Immediate vesting means the shares are not subject to future service-based vesting conditions.

Form 4

Period: 2026-07-10

Director

Transactions

Holdings

Footnotes (3)

[F1]Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
[F2]Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
[F3]Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

Signature

/s/ Lucy Day, Attorney-in-Fact for Kabeer Aziz|2026-07-10

1 file